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Abstract: This study trialled the controlled delivery of growth factors within a biodegradable scaffold
in a large segmental bone defect model. We hypothesised that co-delivery of vascular endothelial
growth factor (VEGF) and platelet derived growth factor (PDGF) followed by bone morphogenetic
protein-2 (BMP-2) could be more effective in stimulating bone repair than the delivery of BMP-2
alone. Poly(lactic-co-glycolic acid) (PLGA ) based microparticles were used as a delivery system
to achieve a controlled release of growth factors within a medical-grade Polycaprolactone (PCL)
scaffold. The scaffolds were assessed in a well-established preclinical ovine tibial segmental defect
measuring 3 cm. After six months, mechanical properties and bone tissue regeneration were assessed.
Mineralised bone bridging of the defect was enhanced in growth factor treated groups. The inclusion
of VEGF and PDGF (with BMP-2) had no significant effect on the amount of bone regeneration at
the six-month time point in comparison to BMP-2 alone. However, regions treated with VEGF and
PDGF showed increased vascularity. This study demonstrates an effective method for the controlled
delivery of therapeutic growth factors in vivo, using microparticles.
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1. Introduction
Most bone fractures do not require intervention and heal spontaneously, stimulated by a
choreographed combination of biological signals [1]. Large bone defects often require intervention
and are difficult and costly to treat, causing pain and disability. Worst case scenarios may lead to
non-union fractures, a chronic and debilitating issue. The clinical gold standard for the treatment of
severe bone defects is autologous bone grafting, but limitations to this approach include donor site
morbidity, pain, and lack of graft material [2]. The most common site for severe bone loss in humans,
resulting in segmental bone defects, is the tibial diaphysis [3].
Autologous bone grafts contain a mixture of cells, mineralised matrix, and signalling molecules.
Research within the field of regenerative medicine has focused on seeking out efficacious alternatives in
an effort to mitigate the limitations of autologous sourcing. Growth factors (GFs) can be used to impart
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bioactive properties onto synthetic scaffolds and bone morphogenetic proteins have been successfully
used clinically for the treatment of long-bone fractures and to enhance spinal fusion [4,5]. However, to
date, clinical approaches using growth factors have not achieved controlled delivery over extended
periods [6–8]. Higher than physiological levels of growth factor have been used in clinical therapies for
bone regeneration and off-label use of these therapies has led to severe clinical complications [9–12]. A
delivery system able to control the release of GFs and deliver a more physiologically relevant dose
could negate these safety risks. Furthermore, extended release could increase the efficacy of a growth
factor-based treatment concept.
Growth factors have attained regulatory approval for bone repair in certain clinical situations [5,13].
None of the current clinical therapies utilise prolonged release or temporal control over GF release.
As a possible result of this, safety concerns have emerged. In 2011, an entire issue of Spine explored
the evolving safety profile of using rhBMP-2 in the treatment of spinal injuries and reconstructive
surgery [14]. It is widely accepted that the clinical complications reported are associated with high
doses and off-label use of GF therapies [9]. Collagen sponges are used, onto which a very high dose
of reconstituted BMP solution is applied immediately prior to implantation into a bone defect site.
OP-1 (Medtronic) and INFUSE (Olympus Bioscience) use up to 3.5 mg BMP-7 and 12 mg BMP-2
respectively [4,5]. While the current clinical use of growth factor therapies is limited it has become
clear that having an appropriate localised dose will offer routes towards enhanced safety [9].
Appropriate administration of growth factors is made difficult by their short in vivo stability.
Accurate half-life values are difficult to obtain and they are often reported as being well below an
hour [15–18]. The high milligram doses of growth factors currently applied clinically could fall
below active physiological concentrations within a day. Since multiple administrations of growth
factors are unfeasible, a controlled delivery of growth factors is desirable for prolonged therapeutic
benefits. Controlled delivery of growth factors from polyesters has previously been reported, however
these studies often demonstrate limited controlled release capability [19,20]. We outline a previously
published method that aims to mitigate incompete release and protein denaturation while building on
the strengths [21,22].
Hydrogels are the most commonly reported delivery system for GFs [23,24] however,
hydrogel scaffolds are generally unable to release GFs for extended periods. Polyesters such
as poly(D,L-lactide-co-glycolide) (PLGA) used to deliver GFs have been reported in literature as
promising alternatives and techniques to combine GFs with polyesters have been reported [25–27] but
no current methods offer the consistency and high entrapment efficiencies required to take them into
the clinic. Polymer microparticles were selected as a GF delivery system because the dry microparticles
have a long storage life and could be attached to different types of load bearing scaffolds or even
injected directly. PLGA is a copolymer of lactide and glycolide and degradation rates of this polymer
can be altered by changing the lactide:glycolide ratio or molecular weight [28,29]; the inclusion of a
more hydrophilic component, such as PLGA-PEG(polyethylene glycol)-PLGA, can be used to provide
additional control over polymer hydration and degradation rates. This work is an adaptation of
previously published methods to improve growth factor delivery by decoupling release kinetics from
polymer degradation [22].
Angiogenesis is important during bone regeneration, as the development of new vessels from
the host vascular network facilitates nutrient/waste transport and the migration of cells into the site
of repair. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis [AAAA]. The
human fracture haematoma has potent angiogenic activity, thought to be due primarily due to VEGF
expression in response to the fracture process [30,31]. Recent research also supports the synergistic
relationship between VEGF and Platelet derived growth factor (PDGF) in the generation of stable
vasculature [32].
In this investigation in a well-characterised and validated large preclinical animal model,
we studied an implant consisting of two elements: a biodegradable structurally supportive, yet
highly porous scaffold made from polycaprolactone (PCL) which was combined with PLGA-based
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microparticles delivering therapeutic GFs immobilised in place with platelet rich plasma. The treatment
of load bearing bones, such as the tibia, requires a mechanically supportive scaffold in combination
with an internal fixation device to provide a structure with appropriate mechanical characteristic to
support the growing bone matrix.
This research was based on the hypothesis that the combined delivery of VEGF, PDGF and BMP-2
would generate more efficient bone regeneration than BMP-2 alone based on the rationale that this
more closely mimics biological events. The angiogenic factors should drive early vasculature and the
BMP-2 should drive bone formation. To test this we used a previously reported PLGA microparticle
delivery system [21,22] to deliver VEGF and PDGF at an early stage and deliver bone morphogenetic
protein 2 (BMP-2) at a later stage. This was compared to the controlled delivery of BMP-2 alone;
GF-free microparticles were used as a control.
2. Results
2.1. Growth Factor Release in vitro
Microparticles containing the angiogenic GFs VEGF and PDGF exhibited release over the first 5
days following an initial burst release (Figure 1A) with the PDGF releasing slightly after the VEGF.
Microparticles containing BMP-2 exhibited an initial burst release followed a sustained delivery of
BMP-2 for 35 consecutive days (Figure 1B). The chosen microparticle formulations demonstrated the
ability to impart different durations of release on the angiogenic and the osteogenic growth factors.
Neither formulation delivered all the GF that was loaded but this is a well known limitation of GF
release formulations [33,34]. All loadings within animals were based on measured GF delivery in vitro.
A theoretical 100% release would have been 10 µg/mg microparticles. It can be seen that the fast
releasing formulation is close to this at approximately 70% whereas the slower formulation is lower at
around 30% (Figure 1A and B respectively).
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Figure 1. Cumulative protein release per mg of polymer microparticles. Release of VEGF and PDGF 
from polymeric microparticles occurred over the first five days (A); in contrast BMP-2 was released 
for 35 days (B). 
X-rays of the treated tibiae post operatively confirmed implant stability. X-rays at the 6 month 
end-point indicated bridging had occurred within 4 of the BMP-2 treated defects, 3 of the combination 
GF treated defects and just one of the control defects. Mineral density in all explants appeared to be 
lower than that of native cortical bone. Representative X-rays of the experimental groups are shown 
(Figure 2). These groups are detailed in Table 1. 
Figure 1. Cumulative protein release per mg of polymer microparticles. Release of VEGF and PDGF
from polymeric microparticles occurred over the first five days (A); in contrast BMP-2 was released
for 35 days (B).
X-rays of the treated tibiae post operatively confirmed implant stability. X-rays at the 6 month
end-point indicated bridging had occurred within 4 of the BMP-2 treated defects, 3 of the combination
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GF treated defects and just one of the control defects. Mineral density in all explants appeared to be
lower than that of native cortical bone. Representative X-rays of the experimental groups are shown
(Figure 2). These groups are detailed in Table 1.
Table 1. Three experimental groups, each with 5 animals. The microparticles deliver a calculated
effective dose of 2 ng/mm3/day from the BMP-2 microparticles and 1 ng/mm3/day from the VEGF
and PDGF microparticles.
Group Growth Factor Loaded Microparticles
GF-free Control microparticles (no growth factor)
Combination VEGF (0.24 mg), PDGF (0.24 mg) and BMP-2 (1.12 mg)
BMP-2 BMP-2 only (1.12 mg)
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Figure 2. Representative X-rays and micro CT reconstructions of the implant at 6 months indicated 
that without growth factor inclusion, the defects failed to bridge (A); and (B). An increased incidence 
of bridging was observed in groups administered with VEGF, PDGF and BMP-2 (C;D), as well as 
groups administered with BMP-2 alone (E;F). 
2.2. Explant Analysis 
Defect regions were explanted from the sheep with both proximal and distal native bone. 
Dynamic compression plates were removed and each sample subjected to mechanical testing at the 
same time and soon after euthanasia to ensure the results were as consistent and biologically relevant 
as possible. Each sample was then scanned with micro computed tomography to provide quantitative 
data prior to fixation and histological analysis. Every sample was subjected to the histological 
analysis method. To do this, the bone was first sectioned longitudionally. One half was fixed and 
resin embedded for sectioning of mineralised bone and the other half was cut laterally into smaller 
parts for decalcification and conventional paraffin histology and immunohistochemistry. 
2.3. Biomechanical Testing 
Three and four defects from the multiple growth factor group and the BMP-2 group, 
respectively, provided enough resistance under load to generate meaningful mechanical data. The 
controls had insufficient mechanical strength to be tested; they failed before any strain could be 
measured. This was due to non-union of the bone. 
. se tative X-rays and micro CT reconstructions of the implant at 6 months indicated that
withou growth factor inclusion, the defects failed to bridge (A); and (B). An i creas d incidence of
bridgin was observ d in groups administered with VEGF, PDGF and BMP-2 (C;D), as well as group
administered with BMP-2 alone (E;F).
2.2. Explant nalysis
efect regions were explanted from the sheep with both proximal and distal native bone. Dynamic
compression plates were removed and each sample subjected to mechanical testing at the same time
and soon after euthanasia to ensure the results were as consistent and biologically relevant as possible.
Each sample was then scanned with micro computed to ography to provide quantitative data prior
to fixation and histological analysis. Every sample was subjected to the histological analysis method.
To do this, the bone was first sectioned longitudionally. One half was fixed and resin embedded for
sectioning of mineralised bone and the other half was cut laterally into smaller parts for decalcification
and conventional paraffin histology and immunohistochemistry.
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2.3. Biomechanical Testing
Three and four defects from the multiple growth factor group and the BMP-2 group, respectively,
provided enough resistance under load to generate meaningful mechanical data. The controls had
insufficient mechanical strength to be tested; they failed before any strain could be measured. This
was due to non-union of the bone.
The GF-free group was excluded from statistical comparisons due to the lack of mechanical data.
Statistical comparisons between the multiple growth factor and BMP-2 groups (Table 1) indicated
no significant differences with respect to ultimate torque and torsional stiffness (p-value = 0.59 and
p-value = 0.61 respectively). The torsion angle at failure indicated higher average values for the
multiple GF group but no significant difference between groups was evident (Figure 3). There was no
differences between GF treated groups but GF-free controls failed to bridge at all.
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Figure 3. Tibial explants were mechanically tested and normalised against the contralateral leg. This
provided the stiffness (A); maximum torque (B); and the angle of failure (C). Boxes indicate one
standard deviation above and below the mean.
2.4. Micro Computed Tomography
The micro CT analysis provided quantitative support for the qualitative conclusions drawn
from the clinical X-rays. It support the X-ray result that just one of the five GF-free defects showed
defect bridging in contrast to 7 of the 10 GF treated defects (4 of the BMP-2 treated defects, 3 of the
combination GF treated defects).
Within the scaffold wall (Figure 4A), both growth factor treated groups demonstrated a higher
bone volume than the scaffold only group. The group treated with BMP-2 alone showed the greatest
increase in bone. This same trend is seen within the scaffold lumen (inside the scaffold) (Figure 4B).
The mean bone volumes inside the scaffold within the growth factor treated groups were, on average,
higher than that of the GF-free group.
All defects exhibited some bone growth in the periphery region (outside the scaffold) ranging
from 409 mm3 to 6013 mm3 (Figure 4B) but there were no significant differences between groups.
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2.5. Histology
Visual inspection of the explants (prior to embed ing) indicated that the PLGA based
microparticles had completely degraded whereas the PCL scaffold remained in place providing
structural stabilit . Once the tissue was processed through xylene, the remaining PCL was
dissolved. Mechanical testing was carried out before histological processing and defor ations i the
tissue/scaf old are at ributed to this destructive mechanical testing.
Representative haematoxylin and eosin (H&E) images from decalcified samples within each
experimental group demonstrated go d integration betwe n the scaffold and the host bone both
proximally and istally (Figure 5). All the regions that contained PCL scaffold ap ear as empty circles
or lines which were once the scaffold struts and had dissolved. Central defect sections cut laterally
indicated bone development de p within the scaffold (Figure 5G–I).
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Figure 5. A schematic of the tibial defect containing the scaffold is shown (A). Three 1-cm regions 
were cut and decalcified to show the integration between scaffold and native bone (proximally and 
distally) and also the mid regions. These regions were sectioned sagittally (B–G) and (K–M) and 
transversely (H–J). 
Entire slices (proximal and distal bone plus the scaffold/defect) from each experimental group 
are shown (Figure 6). Calcified sections (embedded in resin) were stained using Von 
Kossa/MacNeal’s Tetrachrome and Goldners trichrome to identify mineral deposition and cellular 
detail. All groups exhibited some degree of bone ingrowth into the scaffold from both the proximal 
and distal ends. GF treated groups showed bone growth deeper within the scaffold. Sections cut at 
an appropriate plane verified the mineralised defect bridging seen in the micro CT reconstructions 
(Figure 6). The Von Kossa and Goldner’s Trichrome results concur with the micro CT and clinical  
X-ray data. Corresponding micro CT reconstructed sections were compared with the corresponding 
histology sections (Figure 6). This validated both the micro CT threshold levels and the histological 
staining. Direct integration between the scaffold and bone can be seen in the Von Kossa stained 
magnified regions of Figure 6. Blood vessels were also evident in the soft tissue of all groups, these 
are detailed in Figure 6G,J,K. 
Figure 5. A schematic of the tibial defect containing the scaffold is shown (A). Three 1-cm regions
were cut and decalcified to show the integration between scaffold and native bone (proximally and
distally) and also the mid regions. These regions were sectioned sagittally (B–G) and (K–M) and
transversely (H–J).
Entire slices (proxi al and distal bone plus the scaffold/defect) fro each experi ental group
are shown (Figure 6). Calcified sections (embedded in resin) were stained using Von Kossa/MacNeal’s
Tetrachrome and Goldners trichrome to identify mineral deposition and cellular detail. All groups
exhibited some degree of bone ingrowth into the scaffold from both the proximal and distal ends. GF
treated groups showed bone growth deeper within the scaffold. Sections cut at an appropriate plane
verified the mineralised defect bridging seen in the micro CT reconstructions (Figure 6). The Von Kossa
and Goldner’s Trichrome results concur with the icro CT and clinical X-ray data. Corresponding
micro CT reconstructed sections were compared with the corresponding histology sections (Figure 6).
This validated both the micro CT threshold levels and the histological staining. Direct integration
between the scaffold and bone can be seen in the Von Kossa stained magnified regions of Figure 6.
Blood vessels were also evident in the soft tissue of all groups, these are detailed in Figure 6G,J,K.
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stained (M–O) counterparts. More bone growth into the scaffold was observed in growth factor 
treated groups. Magnified regions show both the bone ingrowth and vascular formations (G–L). 
The Goldner’s Trichrome staining technique was used to provide a macroscopic overview and 
compliment the Von Kossa results. The Goldner’s staining results support the micro CT and Von 
Kossa data with respect to bone and soft tissue distribution within the defects. 
Several antibodies were selected to evaluate the newly formed bone tissue and identify any 
differences between groups. Von Willebrand Factor (vWF) is a blood glycoprotein involved in 
hemostasis and by identifying regions of vWF using immunohistochemistry (IHC), we were able to 
identify blood vessels within the defect/scaffold. The mid-region (sectioned laterally) indicated a 
difference between groups. In the GF-free and BMP-2 only groups, very few blood vessels could be 
identified, whereas the VEGF, PDGF and BMP-2 group had a higher density of blood vessels, both 
large and small (Figure 7). 
 
Figure 6. Micro CT slices (A–C) shown with Von Kossa stained (D–F) and Goldner’s Trichrome stained
(M–O) counterparts. More bone growth into the scaffold was observed in growth factor treated groups.
Magnified regions show both the bone ingrowth and vascular formations (G–L).
The Goldner’s Trichrome staining technique was used to provide a macroscopic overview and
compliment the Von Kossa results. The Goldner’s staining results support the micro CT and Von Kossa
data with respect to bone and soft tissue distribution within the defects.
Several antibodies were selected to evaluate the newly formed bone tissue and identify any
differences between groups. Von illebrand Factor (v F) is a blood glycoprotein involved in
hemostasis and by identifying regions of v F using immunohistochemistry (IHC), we were able to
identify blood vessels within the defect/scaffold. The mid-region (sectioned laterally) indicated a
difference between groups. In the GF-free and BMP-2 only groups, very few blood vessels could be
identified, whereas the VEGF, PDGF and BMP-2 group had a higher density of blood vessels, both
large and small (Figure 7).
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will not result in clinically predicatble bone volumes for bridging the defct [40], furthermore it has
been shown that the addition of platelet rich plasma (PRP) does not enhance bridging above that of a
scaffold only [41]. This is the most challenging segmental bone defect model described in the literature
for any regenerative approach strategy. Any repair and bridging of such a defect is a strong indication
of effectiveness of the treatment.
Controlled release of the administered GFs was a novel aspect of this approach, this was also
one of the most challenging aspects. Determining a sustained release therapeutic GF dose was an
estimation based on physiological concentrations. The physiological concentration of BMP-2 in bone
can be calculated as approximately 0.02 ng/mm3 [42] and this is sufficient for bone healing in normal
fractures. Our aim was to use a total GF dose lower than current clinical approaches, which are very
high (3.5 and 12 mg). The literature relating to VEGF and PDGF dosing in controlled release systems
is sparse and administration values were estimated using BMP-2 levels as a benchmark. It has been
shown that excessive VEGF can actually inhibit osteogenesis [43] so the total dose of VEGF was fixed
to 50% that of BMP-2. The chosen formulations released approximately 2 ng/mm3/day BMP-2 and
1 ng/mm3/day VEGF and 1 ng/mm3/day PDGF.
The polymer formulations selected for this study were successful in staggering the release of
growth factors. Both VEGF and PDGF were released at an early stage (up to day 5) and a later-release
of BMP-2 was achieved (Days 25–35). Due to the dense way the microparticles were packed within the
scaffold lumen (Figure S2), we postulated that the actual growth factor release times may be extended
due to non-sink release conditions retarding the passive diffusion of GF from the microparticles.
Microparticles loaded with BMP-2 released 30% of the growth factor in vitro and issues of incomplete
release have been previously reported [44] and widely discussed; reviews have explored the subject in
depth [34]. We postulate that in this case, that interactions between GF and polymer led to adsorption.
Release data from the microparticles was used to determine the mass of microparticles required to
administer to the defect site to deliver an appropriate amount of GF.
It was apparent from histological mineral staining that inclusion of controlled release GFs
increased the depth of bone ingrowth into the scaffolds and increased the incidence of bridging
(4/5 of the BMP-2 treated defects; 3/5 of the combination GF treated defects). Enhanced bridging was
also evident from mechanical testing with bridging localised within the scaffold region. This provided
a physiological appearance to the regenerated bone. Localised osteogenesis was an indicator that the
system provided a localised region of activity. Mechanical testing showed that the defects treated
with VEGF, PDGF and BMP-2 had a greater torsional range than the BMP-2 alone. The cause of this
torsional range remains unclear. A greater sample size would have been necessary to begin to draw
statistically valid conclusions as the treated groups exhibited less regeneration that was anticipated.
The inclusion of microparticles delivering a controlled dose of BMP-2 was able to increase the
bridging of defects in contrast to a GF free scaffold. The addition of VEGF and PDGF to the BMP-2
made no significant improvement over the administration of BMP-2 alone in this ovine critical defect
model at six-months.
4. Materials and Methods
Unless otherwise stated, reagents and consumables were purchased from Sigma-Aldrich (Castle
Hill, Australia).
4.1. Triblock Copolymer Fabrication
Poly(lactic-co-glycolic acid) (PLGA) was supplemented with triblock copolymers consisting of
PLGA and polyethylene glycol (PEG) to tailor protein release. PLGA-PEG-PLGA was prepared and
analysed using previously described methods [22]. Triblock characteristics are detailed in Table 2.
D,L-Lactide and glycolide monomers were obtained from Lancaster Synthesis, Ward Hill, MA, USA and
PURAC, Gorinchem, Netherlands, respectively. The synthesis involved a ring opening polymerisation
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of D,L-lactide and glycolide in the presence of PEG with a small amount of stannous octoate. This
method was reported by Zentner et al. [45] and adapted by Hou et al. [46].
Table 2. Triblock copolymer characteristics [22].
MNa % Mole Lactidea % Mole Glycolidea MNb MWb PDIb
1706-1500-1706 71 29 2442 4022 1.65
adetermined by 1H NMR; bdetermined by GPC.
4.2. Microparticle Fabrication
Microparticles were prepared according to a previously described method involving a
water/oil/water double emulsion solvent evaporation technique [21,22]. PLGA polymers with
lactide:glycolide ratios of 50:50 and 85:15 (PLGA 85:15 DLG 4A 56 kDa and PLGA 50:50 DLG 4.5A
59 kDa) were purchased from Surmodics (Eden Prairie, MN USA). Briefly, PLGA/triblock (1 g)
was dissolved in dichloromethane (5 mL), this formed the oil phase. A protein mixture consisting
of 1 mg growth factor and 9 mg albumin (from human serum) (HSA), or 10 mg HSA for GF-free
microparticles, was dissolved in deionised water (100 µL); this was added to the oil phase. This mixture
was homogenised using an LM5 axial impeller mixer (Silverson machines, Ltd, Chesham, UK) for
2 min at 4000 rpm. This primary water/oil emulsion was quickly added to a 200 mL bath of polyvinyl
alcohol (0.3%) and homogenised again for 2 min at 2000 rpm. This water/oil/water emulsion was stirred
at 300 rpm for 4 h and the microparticles were then washed and collected before freeze drying. The
finished microparticles were free-flowing and of a homogeneous consistency and a mean diameter
of 100 µm.
Three different polymer formulations were selected, one for each growth factor. Two variables
were utilised to control the rate of growth factor release: the ratio of lactide to glycolide in the PLGA
and the weight percentage of PLGA-PEG-PLGA added to the PLGA. The three formulations are
detailed in Table 3. The aim was to stage the release of the three growth factors as VEGF followed
closely by PDGF followed by BMP-2.
Table 3. Polymer formulations used to deliver the growth factors (VEGF, PDGF and BMP-2). Growth
factor release




Recombinant human vascular endothelial growth factor (rhVEGF165) and recombinant human
platelet derived growth factor (rhPDGF-BB) were purchased from PeproTech (London, UK).
Recombinant human bone morphogenetic protein-2 (rhBMP-2) was purchased from Professor Walter
Sebald (University of Wurzbürg, Wurzbürg, Germany). The microparticles that contained HSA and no
growth factor are referred to throughout as GF-free.
An in vitro release study was carried out to determine the release rates of the growth factors from
different polymer formulations.The release of protein over time was quantified in simulated in vivo
conditions. Release studies were continued until all the protein was released or the microparticles
were fully degraded.
Aliquots (50 mg) of the microparticles (triplicate samples from each batch) were suspended
in 1.5 mL phosphate buffered saline (PBS; pH = 7.4); samples were gently rocked in a humidified
incubator at 37 ˝C. At defined time intervals the entire amount of PBS was removed from the 1.5 mL
microcentrifuge tubes and replaced with 1.5 mL fresh PBS; all liquid above the microparticles was
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collected without removing the microparticles. The collected supernatants were stored frozen until
required and then assayed using a Micro BCA assay kit (Thermo Scientific, Paisley, UK) with a standard
curve consisting of human serum albumin (0–40 µg/mL).
4.3. Scaffold Design and Fabrication
Bioresorbable cylindrical scaffolds of medical grade poly-caprolactone (mPCL), (outer diameter:
20 mm, height: 30 mm, inner diameter: 8 mm) were produced by melt extrusion using a BioExtruder
(designed by team at the Centre for Rapid and Sustainable Product Development, Leiria, Portugal) [47].
The structural parameters of the scaffolds were tailored by computer-aided design and included
specifications of 70% porosity with 100% pore interconnectivity within a pore size of 350–500 µm size
and a 0/90˝ lay-down pattern (Figure 1A). This architectural layout was deemed particularly suitable
for load bearing tissue engineering applications since the fully interconnected network of scaffold
fibres could withstand early physiological and mechanical stress in a manner similar to cancellous
bone [41].
Prior to surgery, all scaffolds were surface treated for six hours with 1M sodium hydroxide
(NaOH) and washed five times with phosphate-buffered saline (PBS) to render the scaffold more
hydrophilic. Scaffold sterilization was achieved by incubation in 70% ethanol (followed by complete
evaporation) and UV irradiation for 90 min, rotating the scaffold 3 times.
4.4. Loading of Microparticles into the Scaffold
The microparticles were combined with the scaffold to provide a bioactive GF-containing element
to the structurally supportive mPCL scaffold as shown in Figure 8. The mixture of microparticles
consisted of the same ratio of formulations for each defect and the GF was simply replaced with an
equal loading of albumin. This kept the polymer ratios consistent between groups. The microparticles
were added into the mPCL scaffold architecture by mixing the microparticles within autologous
platelet rich plasma [41] as previously reported. The microparticles were mainly contained in the
central region (lumen) of the scaffold thereby maintaining a high level of porosity in the scaffold wall
(Figure S2). The microparticles were too large to migrate laterally out from the scaffold and the host
tibia essentially blocked the ends. This reduced the likelihood of microparticles migrating from the
defect area.
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Figure 8. Microparticles were incorporated into a polycaprolactone scaffold which is designed
with large pores (>500 icrometers) and fully interconnected honey comb pore architecture (A);
the microparticle/platelet rich plasma mixture was injected into the scaffold from one end (B).
To produce platelet rich plasma (PRP) 80 mL of blood was collected from the jugular vein of each
sheep and transferred into 3.5 mL monovettes supplemented with sodium citrate (3.8%) at a ratio of
9 volumes blood and 1 volume sodium citrate according to procedures reported by Anitua et al. [48].
The citrated blood was transferred to falcon tubes and centrifuged in a standard laboratory centrifuge
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for 20 min at 2400 rpm. Subsequently, the yellow plasma layer from all tubes (from a single sheep) was
transferred to a fresh falcon tube and the platelets were pelleted in a second centrifugation step for
10 min at 3600 rpm [49]. The pellet was resuspended in 1.2 mL of plasma and the platelets counted in
a haemocytometer.
Each sheep was implanted with the same mixture of microparticle formulations, the only
difference being whether the microparticles contained growth factor or not. The microparticles
(2000 mg, detailed in Table 1) were mixed with 1100 µL PRP. This mixture was injected into the lumen
of the scaffold using a modified 5 mL syringe (Figure 8 B). PRP was activated with Thrombin (5 U/mL),
which effectively clotted the microparticles within the scaffold pores and the scaffolds were incubated
at 37 ˝C for one hour before implantation into the defect.
4.5. Implantation
Ovine tibial resections at the diaphysis provide an excellent preclinical test environment for bone
regenerative therapies. A resection of a 3 cm segment is widely accepted to create a non-healing
environment and this model has ben standardised and validated [2,40,41,50,51]. At 6–7 years old,
sheep undergo secondary osteonal remodelling and thus their bone density and microstructure
are comparable to that of humans [50]. Sheep also have an equivalent weight to humans and the
dimensions of their long bones are suitably long to allow the use of human implants [52]. This study
utilised an established and well-tested version of the ovine tibial resection model carried out at the
Medical Engineering Research Facility (MERF), QUT.
Fifteen mature merino sheep (weight 47 ˘ 6 kg, aged 6–7 years) were operated upon as approved
by the University Animal Ethics Committee of the Queensland University of Technology, Brisbane,
Australia (approval number 0900000906). The experimental groups consisted of a scaffold group
containing GF-free microparticles (no growth factor, HSA only) which served as a negative control,
plus two growth factor containing groups as detailed in Table 1. Power analysis of a previous similar
model [2] determined the minimum sample size with a power of 80% (p ď 0.05).
The surgical procedure was carried out using the methods described by Reichert et al. [51]. Briefly,
the right tibia was exposed by a 12 cm longitudinal incision. A broad dynamic compression plate
(DCP) (10 mm ˆ 4.5 mm holes, Synthes, West Chester, PA, USA) was temporarily fixed to the tibia.
Parallel osteotomies were cut using an oscillating saw and a 3 cm middiaphyseal bone segment was
excised. Care was taken to ensure the periosteum was completely removed in the defect zone and
within 1 cm from the defect site on the proximal and distal fragment. The DCP was fixed proximally
using four screws and the scaffold was inserted into the defect. The DCP was then affixed to the distal
fragment using three screws, subjecting the scaffold to a press-fit condition. The wound was then
closed in two layers using sutures.
4.6. Clinical Monitoring
Clinical X-rays (3.2 mAs; 65 kV, Philips Veradius, Amsterdam, NL, USA) were taken immediately
after surgery and after six months healing time in two standard planes (anterior-posterior and
medial-lateral) to determine the healing progress of the defect in the different experimental
groups over time.
After six months the animals (which gained on average 20 to 30% weight) were euthanized by
intravenous injection of 60 mg/kg sodium pentobarbital (Lethabarb, Virbac, Australia) and both the
left (control tibiae) and the right tibiae (containing the scaffold) and 1 cm of surrounding tissue were
explanted for subsequent mechanical testing, micro computed tomography and histological analysis.
4.7. Mechanical Testing
Mechanical testing was carried out at the same time post euthanasia for all samples and all
samples were subjected to testing but only samples with enough mechanical strength to resist torque
were suitable for testing. The fracture fixation plate was carefully removed from the experimental leg.
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Both ends of the tibia were embedded in stainless steel cups using 80 ml of dental acrylic (Paladur,
Heraeus Kulzer, Hanau, Germany) and the bone was then mounted in an Instron 8874 biaxial testing
machine (Instron, Norwood, MA, USA) according to published methods [41]. By leaving as much
soft tissue as possible attached and by wrapping the bones with saline soaked gauze, bone samples
were prevented from drying out. Next, the torsion test was conducted under a compressive load of
50 N and an angular velocity of 0.5 deg/s (right tibia counter clockwise, left tibia clockwise) until the
bones failed and ultimate torque and torsional angle at failure were recorded. The torsional stiffness
was calculated from the slope of the linear portion of the torque-angular displacement curves. Both
ultimate torque and torsional stiffness of the experimental tibia were normalized against the values of
the intact contralateral tibia.
4.8. Micro Computed Tomography
Samples were scanned in a micro computed tomography (microCT) scanner (µCT 40, Scanco
Medical, Brüttisellen, Switzerland) with a voxel size of 36 µm. The X-ray tube was operated at 70kV
and 114 µA. For further analysis, the scans were segmented using a threshold of 437.8 mg HA/ccm,
a Gaussian filter width of 0.8 and filter support of 1.0 to identify mineralised tissue. The segmented
scans were then analysed for bone volume and bone mineral density within the defect using the
software supplied by the manufacturer. For bone volume, the regions of interest were determined as
external callus formation (peripheral), bone formation within the scaffold (scaffold wall) and bone
formation in the inner part of the scaffold (scaffold lumen). Defect bridging was defined as when new
and continuous mineralised bone joined the proximal and distal regions of native bone.
4.9. Histological Sample Preparation
After micro CT scanning, tibial bone specimens were trimmed to five cm length (3 cm defect zone
with 1 cm adjacent cortical bone proximally and distally) and fixed in 4% paraformaldehyde for one
week before being transferred to 70% ethanol. For histological analysis, the mid-defect regions were
sectioned in the transverse and sagittal plane. The sagittally sectioned samples were used for paraffin
embedding. For processing decalcified samples into paraffin, bone samples were decalcified in 15%
EDTA for 6–8 weeks at 4 ˝C. The samples were then dehydrated in increasing ethanol concentrations
in a tissue processor (Excelsior ES, Thermo Scientific, Waltham, MA, USA), and embedded in paraffin.
Five-micrometer sections were obtained using a rotary microtome (RM 2265, Leica, Wetzlar, Germany).
The mineralised bone samples to be cut on the sagittal plane were embedded in
methylmethacrylate resin (Technovit 9100, Heraeus Kulzer, Hanau, Germany). Six-micrometer sections
of the full length of the defect (5 cm long) were cut using a sledge microtome (Polycut S, Reichert
technologies, Depew, NY, USA) and 40–50 µm sections were cut using an EXAKT cutting and grinding
system (EXAKT, Norderstedt, Germany). Sections were cut at two thicknesses because the thicker ones
preserve gross morphology more accurately and the thin sections reveal more cellular detail.
4.10. Von Kossa Staining of Mineralised Sections
Staining using the Von Kossa method was used to identify mineralised tissue which appears
black and a MacNeil’s Tetrachrome stain showed cellular detail in the soft tissue. Resin sections
(6 µm) were deplastified using acetone and rehydrated with serial concentrations of ethanol. Sections
were immersed in silver nitrate solution (5%) for 5 min then developed with a sodium carbonate
formaldehyde solution for 2 min. Slides were rinsed and immersed in Farmer’s Diminisher solution
for 30 s. After further washing, slides were immersed in MacNeal’s Tetrachrome solution for 5 min
with freshly prepared solution. The slides were then dehydrated and mounted using Eukitt mountant.
4.11. Goldner’s Trichrome Staining of Mineralised Sections
Resin sections (40–50 µm) were immersed in xylene followed by descending concentrations of
ethanol. Samples were stained in Weigert’s Haematoxylin then washed. Slides were then stained in
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Ponceau-Fuchsin working solution (10 min) followed by acetic acid (1%). Slides were next immersed in
Orange G solution (20 min) followed by acetic acid (1%). Finally, slides were immersed in Light Green
solution (10 min) followed by acetic acid (1%). Slides were serially dehydrated and then coverslips
were applied using Eukitt mountant.
4.12. Haematoxylin and Eosin Staining of Demineralised Sections
Paraffin sections were deparaffinized with xylene and rehydrated with decreasing concentrations
of ethanol, before being stained with haematoxylin and eosin, dehydrated and mounted with
Eukitt mountant.
4.13. Immunohistochemistry of Demineralised Sections
Paraffin sections were deparaffinised with xylene and rehydrated with decreasing concentrations
of ethanol. Subsequently, sections were rinsed in distilled water and placed in 0.2 M
tris(hydroxymethyl)aminomethane (Tris) buffer prepared at pH = 7.4. Endogenous peroxidase activity
was blocked by incubating the sections in 3% H2O2 in Tris-HCl for 20 min. This was followed by
three washes with Tris buffer (pH = 7.4) for 2 min each. Sections were incubated with Proteinase K
(DAKO, Botany, Australia) for 20 min and subsequently incubated with 2% bovine serum albumin in
DAKO antibody diluent in a humidified chamber at room temperature for 20 min to block nonspecific
binding sites.
Immunohistochemical staining was performed using a primary antibody specific to the markers
of interest. The sections were incubated with the specific antibody in humidified chambers at
4 ˝C overnight (detailed below). Sections were then washed three times for 2 min with Tris
buffer (pH = 7.4) and incubated with peroxidase labelled dextran polymer conjugated to goat
anti-mouse and anti-rabbit immunoglobulins (DAKO EnVision+ Dual Link System Peroxidase,
DAKO, Sydney, Australia) at room temperature in humidified chambers for 60 min. Colour was
developed using a liquid 3,3-diaminobenzidine (DAB) based system (DAKO). Slides were stained
with Haematoxylin to visualise cell nuclei then serially dehydrated and Eukitt coverslip mountant
was used for coverslip mounting.
The selected antibodies were for Osteocalcin (OC4-30 used at a dilution of 1:250, abcam,
Cambridge, MA, USA), Collagen 1 (COL-1 used at a dilution of 1:250, abcam, Cambridge, MA,
USA), CD68 (MCA341GA at a dilution of 1:250, Serotec, Raleigh, NC, USA) and Von Willebrand Factor
(IR527 supplied at a working concentration, DAKO, Botany, Australia).
4.14. Statistical analysis
Statistical analyses for the biomechanical results and for the micro computed tomography scans
(micro CT) were carried out using a Mann-Whitney U test and p-values were adjusted using the Holm
method [53]. All statistical analyses were carried out using the statistical software package R [54].
Results were considered significant at p < 0.05.
5. Conclusions
The group administered with VEGF, PDGF and BMP-2 indicated greater blood vessel density in
the mid-section of the scaffold. This apparent increased vascularisation had little effect on mineralised
bone and bridging at the six-month timepoint. Further study would be required to quantitatively
assess vasculature and ascertain if this increased vasculature results in a better long-term outcome.
It appears that under the conditions evaluated, that the angiogenic GFs added showed no benefit to
defect mineralisation and added significant costs to treatment groups. Further studies of controlled
release BMPs alone are however a strong candidate for future study. By controlling the release of GFs
we can more accurately mimic in vivo invironments. Biomimicry is the key to biologically relevant
treatment approaches.
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Although this study failed to determine the advantage of VEGF and PDGF administration during
osteogenic regeneration, it did show that controlled release formations of BMP-2 can be effective when
applied in a clinically relavent large animal model.
Supplementary Materials: The following are available online at www.mdpi.com/1996-1944/9/4/259/s1.
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